

A multicenter, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult atypical hemolytic uremic syndrome (aHUS) patients who are naive to complement inhibitor therapy

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- at least 18 years old - evidence of active Thrombotic Microangiopathy (TMA)

Exclusion Criteria:

- previous or ongoing treatment with complement inhibitors, including anti-C5 antibody - ADAMTS13 deficiency - positive test for Shiga toxin * direct Coombs test - had a bone marrow transplant or hematopoietic stem cell transplant, or a heart, lung, small bowel, pancreas or live transplant

Conditions & Interventions

Interventions:

Drug: Iptacopan

Conditions:

Blood Disorders, Kidney, Prostate & Urinary, Rare Diseases

Keywords:

Clinics and Surgery Center (CSC)

More Information

Description: To evaluate the efficacy and safety of iptacopan at a dose of 200 mg twice a day for 52 weeks in patients with atypical hemolytic uremic syndrome (aHUS).

Study Contact: Karen Omlung - seve0024@umn.edu

Principal Investigator: Nattawat Klomjit

Phase: PHASE3

IRB

Number: STUDY00020503

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.